eMedicine Specialties > Otolaryngology and Facial Plastic Surgery > Pathology

Skin Cancer: Basal Cell Carcinoma

Author: M Abraham Kuriakose, MD, DDS, FRCS, Chairman, Head and Neck Institute, Amrita Institute of Medical Sciences
Contributor Information and Disclosures

Updated: Dec 11, 2006

Introduction

Background

Basal cell carcinoma (BCC) constitutes approximately 80% of all nonmelanoma skin cancers. The tumors most often appear in individuals aged 40-60 years. BCC's predilection for the head and neck is notable and is related to its primary etiology—solar exposure. Approximately 75-86% of primary BCCs are found on the head or neck. The most common location on the head is the nose, specifically the nasal tip and alae. Australia has the highest incidence of basal cell carcinoma in the world.

Sun exposure is the primary etiologic agent for the development of BCC. Risk is related to skin type and the degree of exposure to sunlight, particularly UV-B radiation. The tumors are more frequent in individuals with fair complexions. Fitzpatrick skin-type scale, which ranges from very fair (skin type I) to very dark (skin type VI), categorizes cutaneous sensitivity to UV radiation. It is based on the individual's tendency to burn and tan and is a good predictor of relative risk among whites. The prevalence of BCC increases in areas of higher altitude and in areas of lower latitude. The incidence of BCC is rising, partly because of atmospheric changes and the increased popularity of sunbathing.

Pathophysiology

BCC primarily affects sun-exposed skin, particularly the upper two thirds of the face.

Frequency

United States

For statistical purposes, BCC and squamous cell carcinomas (SCCs) are grouped as nonmelanoma skin cancer. Incidence of non-melanoma skin cancer varies depending on geographic location. These cancers cause about 300 cases per 100,000 population in Texas and Arizona. The incidence is about half that figure in New York and Maine.

International

Australia has the highest incidence of BCC, ranging from 650-1560 cases per 100,000 population.

Mortality/Morbidity

The estimated annual death rate from this tumor is 0.44 per 100,000 persons. Most of these deaths are due to SCC. BCC rarely causes death. Morbidity is associated with uncontrolled advanced disease.

Race

Whites of Celtic ancestry have the highest risk for BCC. Incidence is low in blacks, Asians, and Hispanics.

Sex

BCC has a male predilection, with a 2:1 male-to-female ratio.

Age

Incidence peaks in persons aged 55-75 years.

Clinical

History

BCC appears as insidious, painless, nonhealing ulcers or nodules on the sun-exposed parts of the body. BCC has a particular predilection for the upper two thirds of the face and is common among white men who are elderly. Because of changing sun-exposing lifestyle patterns among the sexes, the male sex predilection is gradually decreasing. During the clinical evaluation, the patient's social and occupational history of sun exposure, family history of skin cancer, and geographic area of origin are determined to estimate the likelihood that a second primary tumor will develop. Obtain a past history of treatment of the index tumor or other skin tumors. In patients with recurrent tumors, deeper invasion should be expected. Recurrence following radiation therapy is often biologically more aggressive.

Physical

Physical examination should attempt to elicit the subtype of BCC, extent of the tumor, and involvement of important cosmetic and functional structures. Palpation should be used to attempt to estimate the depth of invasion and fixation to the underlying structures. In patients with recurrent or deeply infiltrative tumors, involvement of the facial nerve or branches of the trigeminal nerve should be tested. Facial nerve function can be monitored by comparing facial symmetry during voluntary facial movements with that at rest. Sensory nerve function can be tested and compared to the nonaffected side by means of light touch and pinprick. Orbital invasion can cause diplopia, proptosis, and ophthalmoplegia. Any limitation in ocular movements and/or diplopia should be tested.

BCC seldom causes regional or distant metastasis, with the exception of the metatypical basosquamous type. To evaluate for lymph node metastasis, particular attention should be taken to examine the parotid posterior auricular, suboccipital, and upper cervical groups of lymph nodes. Four different clinicopathologic types of BCC exist, each with distinct biologic behavior.

  • Undifferentiated BCC
  • Nodular or noduloulcerative BCC
    • More than 60% of BCCs belong to this subtype.
    • These lesions appear as well-circumscribed, dome-shaped, pearly nodules with or without ulceration.
  • Superficial BCC
    • This BCC subtype appears as a red scaly patch that resembles the chronic dermatitis predominantly seen in the extremities.
    • These tumors spread superficially and can involve a large surface area.
    • Although satellite islands appear multifocal on standard histopathologic examination, 3-dimensional reconstruction shows that they are interconnected.
  • Morpheaform or sclerosing BCC
    • This form accounts for 10% of lesions.
    • Lesions appear as flat or slightly depressed, fibrotic, and firm.
    • The tumor has a deeply infiltrative character, which may extend beyond the clinically obvious tumor. This feature increases the recurrence potential of morpheaform or sclerosing BCC.
  • Micronodular BCC
    • This type manifests as a plaquelike indurated lesion with poorly demarcated contours.
    • They have increase incidence of recurrence and an aggressive behavior.
  • Other BCCs
    • Aggressive-growth BCC
    • Infiltrative-growth BCC
    • Metatypical BCC
  • Differentiated BCCs
    • Keratotic BCC
    • Infundibulocystic BCC
    • Follicular BCC
    • Pleomorphic BCC

Causes

Incidence of BCC correlates with the amount of accumulated sun exposure. Epidemiologic and molecular studies have confirmed that the UV radiation (UVR) spectrum of sunlight, in synergy with genetic susceptibility, is responsible for BCCs.

  • UV radiation
    • The UVR spectrum of sunlight is divided into 3 parts: long wave UV-A (320-400 nm), intermediate wave UV-B (290-320 nm), and shortwave UV-C (200-290 nm).
      • UV-B and UV-C can modify unsaturated chemical bonds of nucleic acids, which may lead to mutations.
      • UV-C does not penetrate the atmospheric ozone layer; therefore, UV-B is the primary agent responsible for most skin cancers.
      • The UV-A spectrum is absorbed by melanin and, through free-radical transfer, affects cellular deoxyribonucleic acid (DNA).
    • Mutations caused by UVR typically include cytosine (C) to thymine (T) or CC to TT translocation. This process can cause activation of oncogenes or inactivation of tumor suppressor genes, leading to tumor initiation and progression.
  • Host factors
    • In addition to environmental factors, host factors play a critical role in the pathogenesis of BCC. Host factors include racial predilections, genetic syndromes, predisposing syndromes, and immunologic factors.
    • Racial and ethnic factors
      • White race with Celtic ancestry (eg, Irish, Scottish, Welsh) has the highest predilection for BCC.
      • Predilection is primarily related to the pigmentary characteristics of the skin and sun sensitivity.
      • Ability to tan is the most important protective factor.
      • Light eye color; red, blonde, or light-brown hair color; and freckling are strong predictors of BCC.
    • Genetic syndromes
      • Xeroderma pigmentosa is a rare autosomal recessive disorder characterized by hypersensitivity to UVR. It causes defects in DNA repair and synthesis, resulting in cutaneous cancers (eg, BCC, SCC, melanoma).
      • Nevoid basal cell syndrome is an autosomal dominant disorder associated with multiple BCCs, odontogenic keratocysts, calcification of falx cerebri, and rib abnormalities.
      • Epidermodysplastic verruciformis is an autosomal recessive disorder characterized by the development of BCC and SCC from warts.
  • Molecular alterations
    • Inappropriate activation of the hedgehog (HH) signaling pathway is found in both sporadic and familial cases of BCC. This results in loss-of-function mutations in tumor-suppressor protein patched homologue 1 (PTCH1) and gain-of-function mutations in SHH, SMO, and GLI.
    • Mutations in TP53 are found in about 50% of sporadic cases. Most show signature mutations that indicate exposure to UV-B radiation.

More on Skin Cancer: Basal Cell Carcinoma

Overview: Skin Cancer: Basal Cell Carcinoma
Differential Diagnoses & Workup: Skin Cancer: Basal Cell Carcinoma
Treatment & Medication: Skin Cancer: Basal Cell Carcinoma
Follow-up: Skin Cancer: Basal Cell Carcinoma
Multimedia: Skin Cancer: Basal Cell Carcinoma
References

References

  1. American Joint Committee on Cancer. Manual for Staging of Cancer. JB Lippincott;1992.

  2. Baker SR, Swanson NA, Grekin RC. An interdisciplinary approach to the management of basal cell carcinoma of the head and neck. J Dermatol Surg Oncol. Oct 1987;13(10):1095-106. [Medline].

  3. Gallagher RP, Hill GB, Bajdik CD, et al. Sunlight exposure, pigmentary factors, and risk of nonmelanocytic skin cancer & Basal cell carcinoma. Archives of Dermatology. 1995;131:157-63.

  4. Geisse J, Caro I, Lindholm J. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. Journal of the American Academy of Dermatology. 2004;50:722-33. [Full Text].

  5. Miller SJ. Biology of basal cell carcinoma (Part I). J Am Acad Dermatol. Jan 1991;24(1):1-13. [Medline].

  6. Pascal RR, Hobby LW, Lattes R, Crikelair GF. Prognosis of "incompletely excised" versus "completely excised" basal cell carcinoma. Plast Reconstr Surg. Apr 1968;41(4):328-32. [Medline].

  7. Shumack S, Robinson J, Kossard S, et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Archives of Dermatology. 2002;138:1165-71. [Medline][Full Text].

  8. Sober AJ. Diagnosis and management of skin cancer. Cancer. Jun 15 1983;51(12 Suppl):2448-52. [Medline].

  9. Swanson NA. Mohs surgery. Technique, indications, applications, and the future. Arch Dermatol. Sep 1983;119(9):761-73. [Medline].

  10. Swetter SM, Waddell BL, Vazquez MD. Increased effectiveness of targeted skin cancer screening in the Veterans Affairs population of northern California. Preventive medicine. 2003;36:164-71. [Medline][Full Text].

  11. Weber RS, Miller MJ, Goepfert H. Basal and Squamous Cell Skin Cancers of the Head and Neck. Baltimore:. Lippincott Williams & Wilkins;1996:9-33.

Further Reading

Keywords

basal cell carcinoma of the skin, BCC, basal cell epithelioma, rodent ulcer, squamous cell carcinoma, SCC, nodular basal cell carcinoma, noduloulcerative basal cell carcinoma, morpheaform basal cell carcinoma, sclerosing basal cell carcinoma, superficial basal cell carcinoma, basosquamous carcinoma, basisquamous carcinoma, basal squamous cell carcinoma, skin BCC

Contributor Information and Disclosures

Author

M Abraham Kuriakose, MD, DDS, FRCS, Chairman, Head and Neck Institute, Amrita Institute of Medical Sciences
M Abraham Kuriakose, MD, DDS, FRCS is a member of the following medical societies: American Association for Cancer Research, American Head and Neck Society, British Association of Oral and Maxillofacial Surgeons, and Royal College of Surgeons of England
Disclosure: Nothing to disclose.

Medical Editor

Jaime R Garza, MD, DDS, FACS, Consulting Staff, Private Practice
Jaime R Garza, MD, DDS, FACS is a member of the following medical societies: Alpha Omega Alpha, American Academy of Otolaryngology-Head and Neck Surgery, American Cleft Palate/Craniofacial Association, American College of Surgeons, American Medical Association, American Society for Aesthetic Plastic Surgery, American Society of Maxillofacial Surgeons, Texas Medical Association, and Texas Society of Plastic Surgeons
Disclosure: Nothing to disclose.

Pharmacy Editor

Francisco Talavera, PharmD, PhD, Senior Pharmacy Editor, eMedicine
Disclosure: Nothing to disclose.

Managing Editor

M Sherif Said, MD, PhD, Assistant Professor of Pathology, Director of Head and Neck Pathology, Department of Pathology, University of Colorado Health Sciences Center
M Sherif Said, MD, PhD is a member of the following medical societies: American Medical Association, American Society of Clinical Pathologists, American Society of Cytopathology, College of American Pathologists, and Southern Medical Association
Disclosure: Nothing to disclose.

CME Editor

Christopher L Slack, MD, Otolaryngology-Facial Plastic Surgery, Private Practice, Associated Coastal ENT; Medical Director, Treasure Coast Sleep Disorders
Christopher L Slack, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Medical Association
Disclosure: Nothing to disclose.

Chief Editor

Arlen D Meyers, MD, MBA, Professor, Department of Otolaryngology-Head and Neck Surgery, University of Colorado School of Medicine
Arlen D Meyers, MD, MBA is a member of the following medical societies: American Academy of Facial Plastic and Reconstructive Surgery, American Academy of Otolaryngology-Head and Neck Surgery, and American Head and Neck Society
Disclosure: UST Grant/research funds Consulting

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.